Assessing MGMT methylation status and its current impact on treatment in glioblastoma. (January 2015)

• Record Type: Journal Article
• Authors: Berghoff, Anna S; Hainfellner, Johannes A; Marosi, Christine; Preusser, Matthias
• Is Part Of: CNS oncology. Volume 4:Number 1(2015)
• Page Start: 47
• Page End: 52
• Publication Date: 2015-01
• Subjects: biomarker -- glioma -- MGMT promoter methylation -- O6-methylguanine-methyltransferase -- temozolomide; Central nervous system -- Tumors -- Periodicals; 616.99481
• DOI: 10.2217/cns.14.50
• Languages: English
• ISSNs: 2045-0907

Abstract

SUMMARY : MGMT promoter methylation status is a strong and independent prognostic factor in patients with newly diagnosed glioblastoma and a clinically relevant predictive marker in the subpopulation of elderly glioblastoma patients. However, there is still lack of consensus on the optimal assay for reliable MGMT promoter methylation testing and a variety of test are being used in different laboratories. Pyrosequencing is the only method for which an adequately high analytical performance (high intra- and interlaboratory repeatability and reproducibility) has been demonstrated in a fully published ring trial. For clinical decision-making MGMT promoter methylation testing should be performed only in experienced laboratories using meticulous validation of assay accuracy. Ideally, such laboratories should undergo regular accreditation through a quality control consortium.